Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (GB:0R0T)
LSE:0R0T
Holding GB:0R0T?
Track your performance easily
0R0T Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$249.80 - $346.67
Previous Close$317
Volume3.00K
Average Volume (3M)5.04K
Market Cap
$170.59B
Enterprise Value$223.94B
Total Cash (Recent Filing)$9.30B
Total Debt (Recent Filing)$62.65B
Price to Earnings (P/E)54.8
Beta0.51
Next Earnings
Oct 30, 2024EPS Estimate
$5.13Last Dividend Ex-Date
Aug 16, 2024Dividend Yield2.8%
Share Statistics
EPS (TTM)5.80
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume5,045
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.24
Enterprise Value/Gross Profit11.34
Enterprise Value/Ebitda18.79
Forecast
1Y Price Target
$341.88Price Target Upside7.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Amgen News
Bulls Say, Bears Say
Bulls Say
Drug Pipeline And Clinical TrialsAmgen has a rich pipeline of drugs under different stages of clinical trial, which can fuel future growth.
Product Efficacy And Market PotentialUplizna has the potential to capture meaningful MG share with its novel mechanism and better dosing regimen.
Strategic Acquisitions And Portfolio ExpansionAmgen will continue enriching its portfolio through mergers and acquisitions.
Bears Say
Patent ExpiryThe top three best-selling drugs that make up approximately 40% of sales are facing the expiry of their patents in the US.
Product Efficacy ConcernsBoth rocatinlimab and Uplizna therapies appear less efficacious than competing, approved products in their respective indications.
Product PipelineAmgen's late-stage pipeline lacks near-term revenue-makers.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.20% Insiders
21.14% Mutual Funds
0.14% Other Institutional Investors
52.18% Public Companies and
Individual Investors
0R0T FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest share price was $249.80 and its highest was $346.67 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Oct 30, 2024 which is in 24 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 06, 2024. The company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $4.985 by -$0.015.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.8%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $5.13.
How many shares outstanding does Amgen have?
Amgen has 537,329,200 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.97 in its last earnings report, missing expectations of $4.985. Following the earnings report the stock price went down -4.262%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 5B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$341.88 (7.85% Upside)
$341.88 (7.85% Upside)
Blogger Sentiment
Bullish
GB:0R0T Sentiment 90%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.04%
12-Months-Change
Fundamentals
Return on Equity
49.27%
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
0R0T Company Deck
---
0R0T Earnings Call
Q2 2024
0:00 / 0:00
---
0R0T Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
0R0T Stock 12 Month Forecast
Average Price Target
$341.88
▲(7.85% Upside)
Technical Analysis
Best Analysts Covering 0R0T
1 Year
1 Year Success Rate
25/31 ratings generated profit
1 Year Average Return
+15.54%
reiterated a buy rating 11 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 80.65% of your transactions generating a profit, with an average return of +15.54% per trade.
---